S. Kasar

发表

Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution

S. Gabriel, E. Lander, G. Getz, 2015, Nature Communications.

Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia

G. Marti, S. Bauer, S. Kasar, 2016, Oncotarget.

Prognostic value and clinical significance of TCR rearrangements for MRD monitoring in ALL patients

S. Kasar, M. Shahjahani, N. Saki, 2017, Comparative Clinical Pathology.

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL

S. Kasar, S. Fernandes, Jennifer R. Brown, 2018, British journal of haematology.

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

James E. Bradner, Matthew L. Freedman, Alexander J. Federation, 2018, Cancer cell.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

L. Rassenti, T. Kipps, J. Ritz, 2016, Blood.

Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry

M. Faham, S. Kasar, S. Fernandes, 2018, Leukemia & lymphoma.

TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation

M. Jensen, S. Kasar, J. Vlach, 2020, ImmunoHorizons.

Pathways in Specific Cell Types to Promote Inflammation B k TLR7 and TLR8 Differentially Activate the IRF and NF-Przetak,

M. Jensen, S. Kasar, J. Vlach, 2020 .

Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities

J. Ritz, S. Kasar, S. Fernandes, 2015 .

MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders

S. Kasar, Sindhuri Prakash, Yao Yuan, 2012, Leukemia research and treatment.

Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL)

G. Marti, I. Ilev, S. Bauer, 2016, PloS one.

MicroRNAs and Induced Pluripotent Stem Cells for Human Disease Mouse Modeling

S. Kasar, Yao Yuan, C. Underbayev, 2012, Journal of biomedicine & biotechnology.

MicroRNAs and Chronic Lymphocytic Leukemia

G. Marti, S. Kasar, H. Degheidy, 2014 .

Phosphatidylinositol 3-Kinase (PI3K) δ blockade increases genomic instability in B cells

F. Alt, Catherine J. Wu, S. Kasar, 2017, Nature.

Next-Generation Sequencing Reveals Clonal Evolution at the Immunoglobulin Loci in Chronic Lymphocytic Leukemia

V. Carlton, A. Logan, M. Faham, 2014 .

Mutational landscape and underlying mutational processes in chronic lymphocytic leukemia

S. Kasar, J. Brown, 2016, Molecular & cellular oncology.

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

N. Chiorazzi, S. Bruno, S. Kasar, 2021, Frontiers in Oncology.

Therapeutic Implications of Activation of the Host Gene (Dleu2) Promoter for miR-15a/16-1 in Chronic Lymphocytic Leukemia (CLL)

G. Marti, S. Kasar, M. Batish, 2013, Oncogene.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

P. Abrisqueta, F. Awan, S. Kasar, 2015, Clinical Cancer Research.

Altering microRNA miR15a/16 Levels as Potential Therapy in CLL: Extrapolating from the De Novo NZB Mouse Model

S. Kasar, Yao Yuan, D. Vollenweider, 2012 .

Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of Chronic Lymphocytic Leukemia

D. Bonci, A. Addario, S. Kasar, 2011, Genes and Immunity.

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

G. Getz, Charles Lee, S. Kasar, 2016, Clinical Cancer Research.

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).

Emily M. Thrash, S. Tyekucheva, A. Johnson, 2021, Blood.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

M. Kersten, M. Millenson, H. Tilly, 2018, The Lancet. Haematology.

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

S. Tyekucheva, A. Johnson, S. Kasar, 2018, Blood.

Rare Germline Variants in ATM Are Associated with Chronic Lymphocytic Leukemia

S. Gabriel, E. Lander, A. Kamburov, 2017, Leukemia.

Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia

Alexander J. Federation, J. Bradner, S. Kasar, 2015 .

Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.

S. Kasar, S. Kotenko, Yao Yuan, 2012, Molecular immunology.

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL

S. Tyekucheva, S. Kasar, S. Fernandes, 2019, Blood.

Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib

J. Ritz, S. Kasar, S. Fernandes, 2018, Blood.

Preview : Published ahead of advance online publication Rare germline variants in ATM are associated with chronic lymphocytic leukemia

S. Gabriel, E. Lander, A. Kamburov, 2017 .

Phosphatidylinositol 3-Kinase (PI3K) δ blockade increases genomic instability in B cells

F. Alt, Catherine J. Wu, S. Kasar, 2017 .

Phosphatidylinositol 3-Kinase (PI3K) δ blockade increases genomic instability in B cells

F. Alt, Catherine J. Wu, S. Kasar, 2017 .

blockade increases in cells

F. Alt, Catherine J. Wu, S. Kasar, 2022 .

P96 The regulation and pharmacological modulation of immune complex induced production of type III IFN by plasmacytoid dendritic cells

S. Kasar, J. Vlach, Andrew T. Bender, 2020, Poster presentations.